Brief: NW bio announces lifting of clinical hold on DCVax-l phase III trial by FDA
06/02/2017 14:30
Feb 6 (Reuters) - Northwest Biotherapeutics Inc NWBO.PK :
* NW Bio announces lifting of clinical hold on DCVax-l
phase III trial by FDA; progression-free survival events
reached; overall survival events not yet reached
* Trial has accumulated sufficient number of events toward
progression-free survival endpoint, but not yet for overall
survival endpoint
* Co remains blinded to all trial data, and is only
receiving and reporting updates on a blinded basis
Source text for Eikon: ID:nPn2Gpt3Ta
Further company coverage: NWBO.PK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB